Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The kit is developed for quantitative detection of natural and recombinant human IFN-gamma in serum, plasma and cell culture supernatants.
It is suitable for potency assay of CAR-T/NK cell therapy. It has been calibrated against a highly purified human IFN-γ and is evaluated with standard from NIBSC/WHO. Reference Reagent INTERFERON GAMMA (Human, rDNA derived) NIBSC code: 82/587.
It is for research use only.
| Assay Type | Sandwich-ELISA |
| Analyte | IFN-γ |
| Format | 96-wells plate breakable into 12 x 8 wells strips |
| Reactivity | Human |
| Sensitivity | 4 pg/mL |
| Assay Time | 2 hr |
| Sample volume | 50 μL |
| Range | 7.81 pg/mL-1000 pg/mL |
| Sample Type | Cell Culture Supernatants, Plasma, Serum. |
| NIBSC Code | 82/587 |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of IFN-γ is less than 4.0 pg/mL.
Serum Sample: IFN-γ concentrations were measured in two hunderd and eight human serum samples, which were collected from healthy human subjects. The measurements of two hunderd and eight samples are shown in the figure below.
Three types of materials were tested to observe if there were matrix effect (interference). If the concentration of hemoglobin (simulated hemolysis) is less than 3500 mg/dL, the concentration of triglyceride (simulated lipid blood) is less than 3.0 mg/mL, and the concentration of bilirubin (simulated jaundice) is less than 20 mg/dL, testing results will not be affected.
According to the hook effect evaluation, tested results will not be affected when IFN-γ concentration is higher than 250 ng/mL.
High concentrations of human IFN-γ serum samples were diluted with 1:2, 1:4, 1:8, 1:16, 1:32 and 1:64 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of IFN-γ was 99.16%.
Ten replicates of each of four samples containing different IFN-γ concentrations were tested in one assay. Acceptable criteria: CV＜10%.
Four samples containing different concentrations of IFN-γ were tested in the independent assays. Acceptable criteria: CV<15%.
IFN-γ was spiked into five human serum samples, and then analyzed. The average recovery of IFN-γ for serum samples is 95.92%.
| ID | Components | Size |
| CEA006-C01 | Pre-coated Anti-IFN-γ Antibody Microplate | 1 plate |
| CEA006-C02 | Human IFN-γ Standard | 14 μg/48 tests 14 μg×2/96 tests |
| CEA006-C03 | Biotin-Anti-IFN-γ Antibody Con. Solution | 75 μL/48 tests 150 μL/96 tests |
| CEA006-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
| CEA006-C05 | Streptavidin-HRP Con. Solution | 250 μL/48 tests 500 μL/96 tests |
| CEA006-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
| CEA006-C07 | 20×Washing Buffer | 50 mL |
| CEA006-C08 | Sample Dilution Buffer | 15 mL/48 tests 15 mL×2/96 tests |
| CEA006-C09 | Substrate Solution | 12 mL |
| CEA006-C10 | Stop Solution | 6 mL |
Price(USD) : $549.00
Price(USD) :
Price(USD) :
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.
A-Z
